Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gastrointestinal 2Breast 2Other solid neoplasm 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Colorectal Neoplasms 8Melanoma 6Head and Neck Neoplasms 6Colonic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Pancreatic Neoplasms 5Urinary Bladder Neoplasms 4Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Carcinoma, Hepatocellular 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Neoplasms 3Carcinoma, Merkel Cell 3Adenocarcinoma 3Rectal Neoplasms 2Prostatic Neoplasms 2Kidney Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma 2Uterine Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Lung Neoplasms 1

Interventions

Oxaliplatin 29Fluorouracil 25Leucovorin 20Capecitabine 18Irinotecan 17Surveys and Questionnaires 16Bevacizumab 14Cisplatin 12Blood Specimen Collection 11Drug Therapy 10Standard of Care 9Nivolumab 9Gemcitabine 9Cetuximab 7pembrolizumab 6Specimen Handling 6S 1 (combination) 6Endoscopic Mucosal Resection 6Cyclophosphamide 6atezolizumab 5Sunitinib 5Radiotherapy 5Folfox protocol 5Educational Status 5Docetaxel 5fludarabine 4aldesleukin 4Radiosurgery 4Pemetrexed 4Magnetic Resonance Spectroscopy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × cemiplimab × Gastrointestinal × Clear all
NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT04460456 2022-06-30

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Silverback Therapeutics

Phase 1 Unknown
58 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡